Roderick Adrian Slavcev

Dr. Roderick Adrian Slavcev

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Advanced Drug Delivery Reviews
Verified
Journal Article
Open access
HHHaein Huh
Haein Huh
SWShirley Wong
Shirley Wong
JJJesse St. Jean
Jesse St. Jean
RSRoderick Adrian Slavcev
Roderick Adrian Slavcev
The human body is a large reservoir for bacterial viruses known as bacteriophages (phages), which participate in dynamic interactions with their bacterial and human hosts that ultimately affect human health. The current growing interest in human resident phages is paralleled by new uses of phages, including the design of engineered phages for therapeutic applications. Despite the increasing number of clinical trials being conducted, the understanding of the interaction of phages and mammalian cells and tissues is still largely unknown. The presence of phages in compartments within the body previously considered purely sterile, suggests that phages possess a unique capability of bypassing anatomical and physiological barriers characterized by varying degrees of selectivity and permeability. This review will discuss the direct evidence of the accumulation of bacteriophages in various tissues, focusing on the unique capability of phages to traverse relatively impermeable barriers in mammals and its relevance to its current applications in therapy.

1 March 2021 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
DPDeborah Pushparajah
Deborah Pushparajah
SJSalma Jimenez
Salma Jimenez
SWShirley Wong
Shirley Wong
HAHibah Alattas
Hibah Alattas
NNNafiseh Nafissi
Nafiseh Nafissi
RSRoderick Adrian Slavcev
Roderick Adrian Slavcev

19 January 2014 in Applied Microbiology and Biotechnology
Verified
Journal Article
Closed access
PDF file
JNJessica Nicastro
Jessica Nicastro
KSKatlyn Sheldon
Katlyn Sheldon
RSRoderick Adrian Slavcev
Roderick Adrian Slavcev

18 April 2012 in Journal of Nanotechnology
Verified
Journal Article
Open access
PDF file
TKTranum Kaur
Tranum Kaur
NNNafiseh Nafissi
Nafiseh Nafissi
OWOlla Wasfi
Olla Wasfi
KSKatlyn Sheldon
Katlyn Sheldon
SWShawn Wettig
Shawn Wettig
RSRoderick Adrian Slavcev
Roderick Adrian Slavcev
Bacteriophage-based medical research provides the opportunity to develop targeted nanomedicines with heightened efficiency and safety profiles. Filamentous phages also can and have been formulated as targeted drug-delivery nanomedicines, and phage may also serve as promising alternatives/complements to antibiotics. Over the past decade the use of phage for both the prophylaxis and the treatment of bacterial infection, has gained special significance in view of a dramatic rise in the prevalence of antibiotic resistance bacterial strains. Two potential medical applications of phages are the treatment of bacterial infections and their use as immunizing agents in diagnosis and monitoring patients with immunodeficiencies. Recently, phages have been employed as gene-delivery vectors (phage nanomedicine), for nearly half a century as tools in genetic research, for about two decades as tools for the discovery of specific target-binding proteins and peptides, and for almost a decade as tools for vaccine development. As phage applications to human therapeutic development grow at an exponential rate, it will become essential to evaluate host immune responses to initial and repetitive challenges by therapeutic phage in order to develop phage therapies that offer suitable utility. This paper examines and discusses phage nanomedicine applications and the immunomodulatory effects of bacteriophage exposure and treatment modalities.

19 January 2014 in Applied Microbiology and Biotechnology
Verified
Journal Article
Closed access
PDF file
NNNafiseh Nafissi
Nafiseh Nafissi
RSRoderick Adrian Slavcev
Roderick Adrian Slavcev

1 January 2014 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
PDF file
NNNafiseh Nafissi
Nafiseh Nafissi
SASamih Alqawlaq
Samih Alqawlaq
ELEric A Lee
Eric A Lee
MFMarianna Foldvari
Marianna Foldvari
PSPaul Spagnuolo
Paul Spagnuolo
RSRoderick Adrian Slavcev
Roderick Adrian Slavcev
Conventional plasmid DNA vectors play a significant role in gene therapy, but they also have considerable limitations: they can elicit adverse immune responses because of bacterial sequences they contain for maintenance and amplification in prokaryotes, their bioavailability is compromised because of their large molecular size, and they may be genotoxic. We constructed an in vivo platform to produce ministring DNA—mini linear covalently closed DNA vectors—that are devoid of unwanted bacterial sequences and encode only the gene(s) of interest and necessary eukaryotic expression elements. Transfection of rapidly and slowly dividing human cells with ministring DNA coding for enhanced green fluorescent protein resulted in significantly improved transfection, bioavailability, and cytoplasmic kinetics compared with parental plasmid precursors and isogenic circular covalently closed DNA counterparts. Ministring DNA that integrated into the genome of human cells caused chromosomal disruption and apoptotic death of possibly oncogenic vector integrants; thus, they may be safer than plasmid and circular DNA vectors.